An analysis of the diagnostic efficacy of anti-OLA1 autoantibody was conducted across different clinical subgroups, including metastasis status, tumor multiplicity, TNM stage, gender, and AFP status, due to the limited sample size in the Beijing center, data from the other two centers were used. The gene discussed is OLA1; the disease is neoplasm.